Shingles Resources and References

Resources

Vaccination Recommendations

• Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. 2022;71(3):80–84.
• Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR. 2018;67:103–108.
• Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57:1-30. (Note: Zoster vaccine live (Zostavax) is no longer available for use in the United States, as of November 18, 2020.)

Disease-related Resources

• Shingles Overview from AAFP
  Information from the American Academy of Family Physicians
• Resources on Shingles from NINDS
  Information from the National Institute of Neurological Disorders and Stroke

Epidemiology and Vaccine-related Resources

• Pink Book: Herpes Zoster
• Shingles Vaccination: What Everyone Should Know about Shingles Vaccine (Shingrix)
• You Call the Shots: Web-based training for healthcare providers
• Provider and Patient Education
  CDC herpes zoster graphics, podcast, courses, broadcasts, webcasts, slide sets, factsheets
• Shingles Vaccine Information Statement (Shingrix)

References

Journal Articles

Disease-related Articles

• Harpaz R, Leung JW. The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults. Clin Infect Dis. 2019; 69(2):341–344.
• Cohen JI. Herpes zoster. N Engl J Med. 2013;369(18):1766-1767.
• Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48 (Suppl 1):S2-7.
• Hales CM, Harpaz R, Joesoef MR, et al. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med. 2013;159(11):739-745.
• Kawai K, Yawn BP, Wollan P, et al. Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study. Clin Infect Dis. 2016;63(2):221-226.
• Amlie-Lefond C, Jubelt B. Neurologic manifestations of varicella zoster virus infections. Curr Neurol Neurosci Rep. 2009;9(6):430-434.
• Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009;142(3):209-217.
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274-280.
• Sanjay S, Chan EW, Gopal L, et al. Complete unilateral ophthalmoplegia in herpes zoster ophthalmicus. J Neuroophthalmol. 2009;29(4):325-337.
• Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007;74(7):489-494, 496, 498-489 passim.
• Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med. 2007:23(3):615-632, vii-viii.
• Sugisaki K, Yoshida H. Varicella zoster virus meningoencephalitis accompanied by sporadic skin lesions in an older immunocompetent adult. J Infect Chemother. 2007;13(4):270-272.
• Yawn BP, Saddier P, Wollan PC, et al. (2007). A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.
• Gilden DH, Cohrs RJ, Mahalingam R. VZV vasculopathy and postherpetic neuralgia: progress and perspective on antiviral therapy. Neurology. 2005;64(1):21-25.
• Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis. 2004;4(1):26-33.
• Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340-346.
• Levin, MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010;48 (Suppl 1): S14-19.

Vaccine-related Articles

• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older.. NEJM. 2016;375(11):1019-32.
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. NEJM. 2015;372(22):2087-96.
• Cohen J. A New Vaccine to Prevent Herpes Zoster, NEJM. 2015;372:2149-2150.
• Tseng HF, Harpaz R, Luo Y, et al. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged >/=60 Years. J Infect Dis. 2016;213(12):1872-1875.
• Lu PJ, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1-6.
• Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Jama. 2011;305(2):160-6.
• Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343.
• Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices(ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40.
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.

 Top of Page